Neurobiological Financial Statements From 2010 to 2024
| NTIIDelisted Stock | USD 0.0001 0.00 0.00% |
Check Neurobiological Technologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neurobiological Technologies' main balance sheet or income statement drivers, such as , as well as many indicators such as . Neurobiological financial statements analysis is a perfect complement when working with Neurobiological Technologies Valuation or Volatility modules.
Neurobiological |
Neurobiological Technologies Company Return On Equity Analysis
Neurobiological Technologies' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Neurobiological Technologies Return On Equity | 1.0 |
Most of Neurobiological Technologies' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neurobiological Technologies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, Neurobiological Technologies has a Return On Equity of 0.9972. This is 104.16% lower than that of the Biotechnology sector and 102.74% lower than that of the Health Care industry. The return on equity for all United States stocks is notably lower than that of the firm.
Neurobiological Technologies Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Neurobiological Technologies's current stock value. Our valuation model uses many indicators to compare Neurobiological Technologies value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Neurobiological Technologies competition to find correlations between indicators driving Neurobiological Technologies's intrinsic value. More Info.Neurobiological Technologies is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in profit margin category among its peers fabricating about 0.74 of Profit Margin per Return On Equity. The ratio of Return On Equity to Profit Margin for Neurobiological Technologies is roughly 1.35 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Neurobiological Technologies' earnings, one of the primary drivers of an investment's value.About Neurobiological Technologies Financial Statements
Investors use fundamental indicators, such as Neurobiological Technologies' revenue or net income, to determine how well the company is positioned to perform in the future. Although Neurobiological Technologies' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Neurobiological Technologies, Inc. operates under a plan of liquidation and dissolution approved by stockholders in October 2009. The company was founded in 1987 and is based in Emeryville, California. Neurobiological Technologies operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 4 people.
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Other Consideration for investing in Neurobiological Stock
If you are still planning to invest in Neurobiological Technologies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neurobiological Technologies' history and understand the potential risks before investing.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |